Albumin anchored docetaxel lipid nanoemulsion for improved targeting efficiency – preparation, characterization, cytotoxic, antitumor and in vivo imaging studies

References

• AT Chemmanur, GY Wu. (2006). Drug evaluation: albuferon-alpha A — an antiviral interferon-alpha/albumin fusion protein. Curr Opin Investig Drugs 7:750–8
   PubMed Web of Science ®Google Scholar
• J Ciccolini, J Catalin, MF Blachon, et al. (2001). Rapid high-performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction. J Chromatogr B Biomed Sci Appl 759:299–306
   PubMed Web of Science ®Google Scholar
• N Desai, V Trieu, Z Yao, et al. (2006). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–24
   PubMed Web of Science ®Google Scholar
• C Devika Nandan, P Reshmi, U Saji, et al. (2013). Therapeutic properties of boswellic acid nanoparticles in prostate tumor–bearing BALB/c mice model. J Nanopharm Drug Deliv 1:30–7
   Google Scholar
• C Fiehn, U Muller-Ladner, S Gay, et al. (2004). Albumin-coupled methotrexate (MTX-HSA) is a new antiarthritic drug which acts synergistically to MTX. Rheumatology 43:1097–105
   PubMed Web of Science ®Google Scholar
• K Gao, J Sun, K Liu, et al. (2008). Preparation & characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev Ind Pharm 34:1227–37
   PubMed Web of Science ®Google Scholar
• CD Georgiou, K Grintzalis, G Zervoudakis, et al. (2008). Mechanism of Coomassie brilliant blue G-250 binding to proteins: a hydrophobic assay for nanogram quantities of proteins. Anal Bioanal Chem 391:391–403
   PubMed Web of Science ®Google Scholar
• M Goutayer, S Dufort, V Josserand, et al. (2010). Tumor targeting of functionalized lipid nanoparticles: assessment by in vivo fluorescence imaging. Eur J Pharm Biopharm 75:137–47
   PubMed Web of Science ®Google Scholar
• WJ Gradishar, S Tjulandin, N Davidson, et al. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–803
   PubMed Web of Science ®Google Scholar
• MR Green, GM Manikhas, S Orlov, et al. (2006). Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17:1263–8
   PubMed Web of Science ®Google Scholar
• CP Hollis, HL Weiss, M Leggas, et al. (2013). Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J Control Release 172:12–21
   PubMed Web of Science ®Google Scholar
• SSQ Hussaini, H Tanvirul, A Amer, L Xinli. (2014). Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano 8:5423–40
   PubMed Web of Science ®Google Scholar
• NK Ibrahim, B Samuels, R Page, et al. (2005). Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23:6019–26
   PubMed Web of Science ®Google Scholar
• TA John, SM Vogel, C Tiruppathi, et al. (2003). Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 284:L187–96
   PubMed Web of Science ®Google Scholar
• TH Kim, HH Jiang, YS Youn, et al. (2011). Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int J Pharm 403:285–91
   PubMed Web of Science ®Google Scholar
• F Kratz, G Ehling, HM Kauffmann, et al. (2007). Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl) hydrazone derivative of doxorubicin (DOXOEMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Hum Exp Toxicol 26:19–35
   PubMed Web of Science ®Google Scholar
• F Kratz. (2008). Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171–83
   PubMed Web of Science ®Google Scholar
• Q Liu, R Li, Z Zhu, et al. (2012). Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles. Int J Pharm 430:350–8
   PubMed Web of Science ®Google Scholar
• Y Liu, J Sun, H Lian, et al. (2014). Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution. J Pharm Sci 103:1538–47
   PubMed Web of Science ®Google Scholar
• S Muzammil Afzal, V Kishan. (2013). Preparation, characterization and in vitro evaluation of stealth docetaxel lipid nanoemulsions for efficient cytotoxicity. IJDD 5:188–95
   Google Scholar
• J Porath, P Flodin. (1959). Gel filtration: a method for desalting and group separation. Nature 183:1657–9
   PubMed Web of Science ®Google Scholar
• K Prabhakar, S Muzammil Afzal, G Surendar, et al. (2012). Albumin coupled lipid nanoemulsions of diclofenac for targeted delivery to inflammation. Nanomed: Nanotechnol Biol Med 8:1162–71
   PubMed Web of Science ®Google Scholar
• M Priyanka, T Amruta, S Anjali, et al. (2014). In situ synthesized BSA capped gold nanoparticles: effective carrier of anticancer drug methotrexate to MCF-7 breast cancer cells. Mater Sci Eng: C 34:158–67
   PubMed Web of Science ®Google Scholar
• Z Shen, Y Li, K Kohama, et al. (2011). Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres. Pharmacol Res 63:51–8
   PubMed Web of Science ®Google Scholar
• J Shougang, G Xianfeng, Z Xiuhua, et al. (2015). Preparation, characterization, and antitumor activities of folate-decorated docetaxel-loaded human serum albumin nanoparticles. Drug Delivery 22:206–13
   PubMed Web of Science ®Google Scholar
• R Sinha, GJ Kim, S Nie, et al. (2006). Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 5:1909–17
   PubMed Web of Science ®Google Scholar
• G Stehle, A Wunder, H Sinn, et al. (1997). Pharmacokinetics of methotrexate-albumin conjugates in tumor bearing rats. Anticancer Drugs 8:835–44
   PubMed Web of Science ®Google Scholar
• A Taheri, R Dinarvand, F Ahadi, et al. (2012). The in vivo antitumor activity of LHRH targeted methotrexate–human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice. Int J Pharm 431:183–9
   PubMed Web of Science ®Google Scholar
• A Taitz, G Petruzzelli, AS Pak, et al. (1995). Immune parameters of mice bearing human head and neck cancer. Cancer Immunol Immunother 40:283–91
   PubMed Web of Science ®Google Scholar
• C Unger, B Häring, M Medinger, et al. (2007). Phase I and pharmacokinetic study of the (6-maleimidocaproyl) hydrazone derivative of doxorubicin. Clin Cancer Res 13:4858–66
   PubMed Web of Science ®Google Scholar
• AA van de Loosdrecht, RH Beelen, GJ Ossenkoppele, et al. (1994). A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods 174:311–20
   PubMed Web of Science ®Google Scholar
• S Vandana, DV Kohli, SK Jain. (2005). Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil. J Drug Target 13:245–50
   PubMed Web of Science ®Google Scholar
• E Varshika, K Prabhakar, V Kishan. (2009). Preparation, characterization and in vivo pharmacodynamic evaluation of parenteral diclofenac submicron lipid emulsions. PDA J Pharm Sci Technol 63:380–9
   PubMedGoogle Scholar
• I Venkateshwarlu, K Prabhakar, A Mubarak, et al. (2010). Development and in vitro cytotoxic evaluation of parenteral docetaxel lipid nanoemulsions for application in cancer treatment. PDA J Pharm Sci Technol 64:233–41
   PubMedGoogle Scholar
• AN Vis, A van der Gaast, BW van Rhijn, et al. (2002). A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy. Cancer Chemother Pharmacol 49:342–5
   PubMed Web of Science ®Google Scholar
• H Zhang, J Dou, Y Zhai, et al. (2014). Advances in the formulations of noninjection administration of docetaxel. J Drug Target 22:87–94
   PubMed Web of Science ®Google Scholar